医学
高尿酸血症
血压
肾功能
内科学
糖尿病
噻嗪
尿酸
痛风
利尿剂
肾脏疾病
心脏病学
风险因素
置信区间
内分泌学
作者
Pengli Zhu,Fan Lin,Chunjin Lin,Donghuang Hong,Kaiyang Lin,Hui Chen
出处
期刊:Journal of Cardiovascular Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2012-09-07
卷期号:13 (11): 741-746
被引量:8
标识
DOI:10.2459/jcm.0b013e328358527c
摘要
As elevated serum uric acid (SUA) is an independent risk factor for hypertension, we examined whether baseline SUA may influence the blood pressure (BP) response to antihypertensive medications.Data from 1648 inpatients with essential, uncontrolled hypertension on admission were analyzed retrospectively. Patients taking loop or thiazide diuretics or hypouricemic agents were excluded. The BP response to treatment was based on the BP change from admission (baseline) to discharge.The mean age was 66.7 ± 11.5 years, the average BP was 156.1/85.5 mmHg and the average estimated glomerular filtration rate (eGFR) was 80.07 ± 21.69 ml/min per 1.73 m. Twenty-five percent of the patients had chronic kidney disease and 32% had diabetes. The average duration of hospitalization was 14.3 ± 5.3 days. In 1149 patients with normal renal function (eGFR ≥60 ml/min per 1.73 m), those with hyperuricemia (SUA >420 μmol/l in men and >360 μmol/l in women) had more metabolic disorders (P < 0.05), higher baseline diastolic BP (P < 0.05), greater antihypertensive therapeutic intensity score (TIS) at baseline and discharge (P < 0.01), more diuretic use at discharge (P < 0.01) and less systolic BP reduction in response to antihypertensive therapy (P < 0.01). After adjustment for age, diabetes, BMI, baseline BP, lipid disorders, baseline TIS and eGFR, multiple linear regression using the data from all patients indicated that hyperuricemia was associated with a 5.3 mmHg less systolic BP reduction [95% confidence interval (CI): 3.1-7.4 mmHg, P < 0.01] in men, and a 2.6 mmHg less systolic BP reduction (95% CI: 0.5-4.6 mmHg, P = 0.02) in women.Hyperuricemia may be an independent risk factor for BP control in elderly hypertensive patients during hospitalization.
科研通智能强力驱动
Strongly Powered by AbleSci AI